<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">Remdesivir is a phosphoramidite pro-drug of an adenine derivative with a chemical structure similar to Tenofovir alafenamide, an approved inhibitor of HIV reverse transcriptase. Remdesivir had broad-spectrum activity against a diverse range of coronaviruses, including human CoVs, zoonotic bat CoVs, and pre-pandemic zoonotic CoVs, in addition to Ebola in cell culture and animal models 
 <xref rid="b0375" ref-type="bibr">[75]</xref>. The results of the latest studies suggested that Remdesivir can inhibit 2019-nCoV 
 <xref rid="b0345" ref-type="bibr">[69]</xref>, 
 <xref rid="b0380" ref-type="bibr">[76]</xref>. Moreover, a phase III clinical trial of Remdesivir against COVID-19 was launched in Wuhan on February 4th, 2020. Remdesivir is not expected to be widely available as an experimental drug for treating a vast number of patients 
 <xref rid="b0385" ref-type="bibr">[77]</xref>. However, the Food and Drug Administration (FDA) has approved Remdesivir as an effective COVID-19 treatment 
 <xref rid="b0390" ref-type="bibr">[78]</xref>.
</p>
